A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus

Trial Profile

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs MK 5160 (Primary) ; Glucose; Insulin glargine
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MK-5160-002
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Apr 2017 Planned End Date changed from 6 Oct 2017 to 30 Nov 2017.
    • 28 Apr 2017 Planned primary completion date changed from 6 Oct 2017 to 30 Nov 2017.
    • 28 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top